Drug intelligence / Profile preview

alamifovir

Development stage: Discontinued
Lead developer: Mitsubishi Tanabe
Modality: Small Molecules
Administration: Oral

Overview

Alamifovir is a purine nucleotide analogue prodrug developed as an antiviral agent specific for hepatitis B virus (HBV), including both wild-type and lamivudine-resistant strains. It acts by inhibiting the protein priming reaction and the packaging reaction, thereby decreasing HBV replication—a mechanism distinct from conventional nucleoside/nucleotide reverse transcriptase inhibitors. Alamifovir demonstrated potent preclinical efficacy, with an EC50 of 0.027 μM against wild-type HBV and higher EC50 values (2.6–3.3 μM) against lamivudine-resistant mutants, indicating activity even in resistant cases. The drug was under development by Mitsubishi Pharma Corporation but its development has been discontinued[1][2][3].

Other names: alamifovir

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on alamifovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alamifovir.

Explore the full profile